NAD+ Augmentation as a Disease-Modifying Strategy for Neurodegeneration: Review

SynopsisNeurodegenerative diseases are a growing global health problem with no current treatments that slow or stop their progression. Boosting nicotinamide adenine dinucleotide (NAD+) has emerged ...

Combined Metabolic Activators Improve Brain and Liver Function in Alzheimer's and Parkinson's Disease: Preclinical Findings

Synopsis Mitochondrial dysfunction and metabolic problems are major contributors to neurodegenerative diseases such as Parkinson’s (PD) and Alzheimer’s (AD). Research shows that combined metabolic...

Nicotinamide Riboside Supplementation with Metabolic Activators Improves Cognitive Function in Parkinson’s Disease: Clinical Findings

Objectives To investigate whether supplementation of combined metabolic activators (CMA) consisting of NR, L-carnitine tartrate, serine, and N-acetyl-L-cysteine (NAC), could be used to treat Parki...

Nicotinamide Riboside Protects Dopamine Neurons in Parkinson's Disease: Preclinical Findings

Synopsis This study identified the essential role of NAMPT, an enzyme that helps produce NAD+, in protecting dopaminergic neurons—the brain cells that control movement and are lost in Parkinson’s ...

Effects of Nicotinamide Riboside on Mitochondrial Health and Dopamine in Parkinson's Disease: Preclinical Findings

SynopsisParkinson's disease (PD) involves mitochondrial dysfunction, reduced proteasome activity, and dopamine depletion. NR activated mitochondrial function in C. elegans, rescuing α-synuclein-rel...

Nicotinamide Riboside Improves Survival and Motor Function in Parkinson’s Disease: Preclinical Findings

Synopsis Parkinson’s disease (PD) is a neurodegenerative disorder marked by the loss of dopamine-producing neurons, leading to motor dysfunction and other symptoms. This study investigated how nic...

High-Dose Nicotinamide Riboside Supplementation Provides Benefits in Parkinson’s Disease: Clinical Findings

Objectives To assess the safety of high-dose NR through the absence of clinically significant adverse events, and assess short-term tolerability and impacts on NAD+, as well as clinical severity o...

Nicotinamide Riboside Supplementation Does Not Disrupt Methylation, Including in Individuals with MTHFR Mutations: Clinical Findings

Objectives To investigate the impact of NR supplementation on DNA methylation patterns in the blood cells and muscle tissues of newly diagnosed, dopaminergic treatment-naïve Parkinson's disease (P...

Combined Metabolic Activators Including Nicotinamide Riboside Improve Metabolism in Alzheimer's and Parkinson's Disease: Preclinical Findings

Synopsis Neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD) are linked to metabolic problems, including mitochondrial dysfunction. This study analyzed human brai...

Nicotinamide Riboside Supplementation Benefits in Early Parkinson's Disease: Clinical Findings

Objectives To assess the safety, tolerability, and cerebral penetration of NR therapy in Parkinson's disease (PD) patients, as well as determine if NR has an impact on their neurometabolic profile...

Nicotinamide Riboside Reduces Chemotherapy-Induced Peripheral Neuropathy and Suppresses Tumor Growth: Preclinical Findings

Synopsis Nicotinamide riboside (NR) is a vitamin B3 precursor of NAD+ that blunts diabetic and chemotherapy-induced peripheral neuropathy in preclinical models. This study tested whether NR also r...

Fixing Imbalanced NAD Metabolism Reduces Effects of Telomere Dysfunction: Preclinical Findings

Synopsis Short telomeres cause diseases like dyskeratosis congenita (DC), which lack effective treatments. This study found that cells from DC patients and telomerase-deficient mice have low NAD+ ...

Nicotinamide Riboside Prevents SARM1-Induced NAD+ and ATP Depletion: Preclinical Findings

Synopsis Mitochondrial dysfunction is a key feature of neurodegenerative diseases like Parkinson’s. SARM1 promotes nerve damage by breaking down NAD+, and its activity is increased when phosphoryl...